FAST Phase 2 Trial: IMAB362 for Gastric, GEJ, and Esophageal Cancers - 102164

Spotlight
Video

FAST Phase 2 Trial: IMAB362 for Gastric, GEJ, and Esophageal Cancers

Loading........
Description: Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of the results of the FAST Phase 2 Trial, which was presented by Martin H. Schuler, MD at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 4028: Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction (GEJ), and esophageal cancers: Results from the FAST Study
Shared By : AnnualMeeting2017
Posted on : 06/07/17
Added : 1 year ago